NasdaqCM - Nasdaq Real Time Price USD

ZyVersa Therapeutics, Inc. (ZVSA)

Compare
1.0502 -0.0198 (-1.85%)
At close: December 13 at 4:00:00 PM EST
1.0200 -0.03 (-2.88%)
After hours: December 13 at 4:19:49 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
9,626.4500
14,420.7740
13,013.0640
7,704.3760
11,833.0580
Operating Income
-9,626.4500
-14,420.7740
-13,013.0640
-7,704.3760
-11,833.0580
Net Non Operating Interest Income Expense
-131.8920
0.4570
-427.5420
-821.3660
-516.4500
Other Income Expense
-408.4000
-93,333.4590
-607.0010
441.5810
-333.6580
Pretax Income
-21,916.5970
-107,753.7760
-14,047.6070
-8,084.1610
-12,683.1660
Tax Provision
-586.3610
-9,455.8300
--
--
--
Net Income Common Stockholders
-21,330.2360
-106,246.1550
-24,063.4440
-8,084.1610
-12,683.1660
Diluted NI Available to Com Stockholders
-21,330.2360
-106,246.1550
-24,063.4440
-8,084.1610
-12,683.1660
Basic EPS
491.97
-1.09k
-346.10
-139.88
-183.27
Diluted EPS
491.97
-1.09k
-346.10
-139.88
-183.27
Basic Average Shares
665.9380
97.5030
69.2050
57.7920
69.2050
Diluted Average Shares
665.9380
97.5030
69.2050
57.7920
69.2050
Total Operating Income as Reported
-21,784.7050
-107,754.2330
-13,013.0640
-7,704.3760
-11,833.0580
Total Expenses
9,626.4500
14,420.7740
13,013.0640
7,704.3760
11,833.0580
Net Income from Continuing & Discontinued Operation
-21,330.2360
-98,297.9460
-14,047.6070
-8,084.1610
-12,683.1660
Normalized Income
-9,497.2654
-13,177.8314
-13,440.6060
-8,525.7420
-12,349.5080
Interest Income
--
0.4570
--
--
--
Interest Expense
582.5370
--
427.5420
821.3660
516.4500
Net Interest Income
-131.8920
0.4570
-427.5420
-821.3660
-516.4500
EBIT
-9,626.4500
-14,420.7740
-13,620.0650
-7,262.7950
-12,166.7160
EBITDA
-9,616.9170
-14,410.3740
-13,610.1970
-7,252.3950
-12,156.3160
Reconciled Depreciation
9.5330
10.4000
9.8680
10.4000
10.4000
Net Income from Continuing Operation Net Minority Interest
-21,330.2360
-98,297.9460
-14,047.6070
-8,084.1610
-12,683.1660
Total Unusual Items Excluding Goodwill
-12,158.2550
-93,333.4590
-607.0010
441.5810
-333.6580
Total Unusual Items
-12,158.2550
-93,333.4590
-607.0010
441.5810
-333.6580
Normalized EBITDA
2,541.3380
78,923.0850
-13,003.1960
-7,693.9760
-11,822.6580
Tax Rate for Calcs
0.0000
0.0001
--
--
--
Tax Effect of Unusual Items
-325.2844
-8,213.3444
--
--
--
12/31/2020 - 2/11/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SPRC SciSparc Ltd.
0.2712
+6.35%
 
PXMD PaxMedica, Inc.
0.0700
0.00%
 
BDRX Biodexa Pharmaceuticals Plc
4.2000
-6.67%
 
NKGN NKGen Biotech, Inc.
0.4998
+1.01%
 
INAB IN8bio, Inc.
0.2848
-2.00%
 
ENSC Ensysce Biosciences, Inc.
5.62
-8.17%
 
KPRX Kiora Pharmaceuticals, Inc.
3.3200
-6.74%
 
REVB Revelation Biosciences, Inc.
0.3600
-12.75%
 
ERNA Eterna Therapeutics Inc.
0.2890
-0.28%
 
TCBP TC Biopharm (Holdings) Plc
0.5290
-9.40%